Tradestie Institutional Equity Comparison Engine

IONS vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IONS
IONS 90.9x vs SYRE N/M Fwd P/E
Growth & Margin Winner SYRE
Op Margin -58.8% vs 0.0% ยท YoY +54.9% vs +0.0%
Momentum & Technical Winner SYRE
1Y -59.1% vs +341.7% ยท 52W Pos 2% vs 88%
Options & Structure Winner SYRE
BREAKDOWN (17th %ile IV) vs UNCLASSIFIED (10th %ile IV)
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IONS -59.1% SYRE +341.74% Spread: +400.84 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IONS TTM Op. Margin: -58.8% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONS vs SYRE. Trailing 12-month operating profitability (IONS -58.8% vs SYRE 0.0%) and valuation multiples (IONS 90.9x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IONS (4) vs SYRE (6)
Institutional Metric IONS SYRE Criterion Row Winner
Market Capitalization Scale $4.7B $9.8B Larger Scale SYRE
Trailing P/E Ratio Valuation 90.9x N/M Lower Multiple IONS
Forward P/E Ratio Valuation 90.9x N/M Lower Multiple IONS
Revenue Growth (YoY) Growth +54.9% +0.0% Higher Growth IONS
Operating Margin (TTM) Profitability -58.8% 0.0% Higher Margin SYRE
Net Profit Margin Profitability -56.9% 0.0% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -108.0% -35.0% Higher ROE SYRE
52-Week Range Position Momentum 2% ($27โ€“$87) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 86% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 63.9 / 100 (BUY) 44.4 / 100 (HOLD) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IONS vs SYRE Buy Guide
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IONS nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.